Rasagiline
As of the edition of 20 October 2026, Rasagiline is a small molecule: marketed, first approved in 2005 (EU); acts on MAOB; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Azilect
- First approved
- 21 February 2005 (EU)
- Approvals on record
- 6 in 3 regions
- Holder of the most recent approval
- Takeda; 3 holders in all
- Registered trials
- 47, 3 stopped early
- Disease areas
- Nervous system; Nutrition and metabolism; Mental health; Chemically induced; Eye
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Teva.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Rasagiline.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MAOB | Amine oxidase [flavin-containing] B | P27338 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 6 | 0 | 0 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 6 | 6 | 0 | 0 |
| Phase 3 | 18 | 17 | 0 | 1 |
| Phase 4 | 11 | 8 | 0 | 2 |
| All trials | 47 |